• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ImmunityBio, Inc. - Common Stock (NQ:IBRX)

    12.06 +2.23 (+22.66%)
    Streaming Delayed Price Updated: 3:23 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 69,990,977
    Open 10.15
    Bid (Size) 12.05 (600)
    Ask (Size) 12.06 (300)
    Prev. Close 9.830
    Today's Range 9.950 - 12.28
    52wk Range 1.830 - 11.00
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth ↗
    ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types. 
    Via Stocktwits
    News headline image
    Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗
    On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion. 
    Via The Motley Fool
    Topics Stocks

    Performance

    YTD
    +496.9%
    +496.9%
    1 Month
    +94.2%
    +94.2%
    3 Month
    +460.8%
    +460.8%
    6 Month
    +435.9%
    +435.9%
    1 Year
    +274.4%
    +274.4%

    More News

    Read More
    News headline image
    ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
    From ImmunityBio, Inc.
    Via Business Wire
    Check out the stocks that are attracting the most attention and driving market activity. ↗
    Via Chartmill
    News headline image
    Why ImmunityBio Stock Is Soaring Again Today ↗
    Via The Motley Fool
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗
    Via Stocktwits
    News headline image
    ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    News headline image
    IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough ↗
    Via Stocktwits
    News headline image
    ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
    Via Stocktwits
    News headline image
    ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics ETFs Economy Government
    News headline image
    IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug ↗
    Via Stocktwits
    Topics Government
    News headline image
    ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
    Via Finterra
    Topics Lawsuit
    News headline image
    ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗
    Via Stocktwits
    News headline image
    ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics ETFs Economy Government
    News headline image
    Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls ↗
    Via Stocktwits
    News headline image
    Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer ↗
    Via The Motley Fool
    Topics Initial Public Offering Stocks
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Why ImmunityBio Stock Is Soaring Today ↗
    Via The Motley Fool
    Discover the most active stocks in Wednesday's session. ↗
    Via Chartmill
    Top movers in Wednesday's session ↗
    Via Chartmill
    News headline image
    IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗
    Via Stocktwits

    Frequently Asked Questions

    Is ImmunityBio, Inc. - Common Stock publicly traded?
    Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
    What exchange does ImmunityBio, Inc. - Common Stock trade on?
    ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
    The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
    What is the current price of ImmunityBio, Inc. - Common Stock?
    The current price of ImmunityBio, Inc. - Common Stock is 12.06
    When was ImmunityBio, Inc. - Common Stock last traded?
    The last trade of ImmunityBio, Inc. - Common Stock was at 02/24/26 03:23 PM ET
    What is the market capitalization of ImmunityBio, Inc. - Common Stock?
    The market capitalization of ImmunityBio, Inc. - Common Stock is 4.72B
    How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
    ImmunityBio, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.